International Journal of Cancer最新文献

{"title":"Socio-economic inequalities in second primary cancer incidence: A competing risks analysis of women with breast cancer in England between 2000 and 2018.","authors":"Ruchika Golani, Eva Kagenaar, Jérémie Jégu, Aurélien Belot, Suping Ling","doi":"10.1002/ijc.35320","DOIUrl":"https://doi.org/10.1002/ijc.35320","url":null,"abstract":"<p><p>We aimed to investigate socio-economic inequalities in second primary cancer (SPC) incidence among breast cancer survivors. Using Data from cancer registries in England, we included all women diagnosed with a first primary breast cancer (PBC) between 2000 and 2018 and aged between 18 and 99 years and followed them up from 6 months after the PBC diagnosis until a SPC event, death, or right censoring, whichever came first. We used flexible parametric survival models adjusting for age and year of PBC diagnosis, ethnicity, PBC tumour stage, comorbidity, and PBC treatments to model the cause-specific hazards of SPC incidence and death according to income deprivation, and then estimated standardised cumulative incidences of SPC by deprivation, taking death as the competing event. Multiple imputation was performed to account for missing data. Among 649,905 included women, 47,399 SPCs and 171,223 deaths occurred during 4,269,042 person-years of follow-up. Income deprivation was consistently associated with an increased rate of SPC incidence (cause-specific hazard ratio for the most vs. least deprived quintile: 1.29; 95% CI: 1.25, 1.33) and of death (1.36; 1.34, 1.38), translating into an absolute risk difference (the most vs. least deprived quintile) of 1.3% (95% CI: 1.0, 1.5) for SPC incidence and 4.9% (95% CI: 4.6, 5.1) for death at 10 years. Women with PBC from deprived areas in England faced a substantially higher risk of SPC than their counterparts. Future research is warranted to understand mechanisms for observed inequalities to inform strategies to monitor, prevent, and identify SPC in women with PBC.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143035475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epigenomics-guided precision oncology: Chromatin variants in prostate tumor evolution.","authors":"Kira Furlano, Tina Keshavarzian, Nadine Biernath, Annika Fendler, Maria de Santis, Joachim Weischenfeldt, Mathieu Lupien","doi":"10.1002/ijc.35327","DOIUrl":"https://doi.org/10.1002/ijc.35327","url":null,"abstract":"<p><p>Prostate cancer is a common malignancy that in 5%-30% leads to treatment-resistant and highly aggressive disease. Metastasis-potential and treatment-resistance is thought to rely on increased plasticity of the cancer cells-a mechanism whereby cancer cells alter their identity to adapt to changing environments or therapeutic pressures to create cellular heterogeneity. To understand the molecular basis of this plasticity, genomic studies have uncovered genetic variants to capture clonal heterogeneity of primary tumors and metastases. As cellular plasticity is largely driven by non-genetic events, complementary studies in cancer epigenomics are now being conducted to identify chromatin variants. These variants, defined as genomic loci in cancer cells that show changes in chromatin state due to the loss or gain of epigenomic marks, inclusive of histone post-translational modifications, DNA methylation and histone variants, are considered the fundamental units of epigenomic heterogeneity. In prostate cancer chromatin variants hold the promise of guiding the new era of precision oncology. In this review, we explore the role of epigenomic heterogeneity in prostate cancer, focusing on how chromatin variants contribute to tumor evolution and therapy resistance. We therefore discuss their impact on cellular plasticity and stochastic events, highlighting the value of single-cell sequencing and liquid biopsy epigenomic assays to uncover new therapeutic targets and biomarkers. Ultimately, this review aims to support a new era of precision oncology, utilizing insights from epigenomics to improve prostate cancer patient outcomes.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143031749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cervical cancer incidence rates considering migration status in mainland China using Bayesian model-Estimation based on 2016 cancer registry data.","authors":"Linlin Du, Huixin Sun, Liping Tang, Shuxiu Hao, Chen Feng, Guijin Li, Yu Zhang, Hong Jin, Cunqi Lv, Qingyu Zeng, Cheng Wang, Jiacheng Li, Xinshu Wang, Rong Ma, Tong Wang, Qi Li","doi":"10.1002/ijc.35346","DOIUrl":"https://doi.org/10.1002/ijc.35346","url":null,"abstract":"<p><p>In mainland China, cancer registration relies on household-registered populations, overlooking migrant populations. Estimating cervical cancer incidence among permanent residents, including migrants, offers a more accurate representation of the true burden. The data from 487 cancer registries across China in 2016 were analyzed using a Bayesian spatial regression model with the integrated nested Laplace approximation-stochastic partial differential equation method. The study estimated cervical cancer incidence among household-registered populations and adjusted for migrant populations using a weighting method based on interprovincial distribution and age stratification to derive the incidence of cervical cancer in the permanent residents. Data from the China Population Census, the China Migrants Dynamic Survey, and the Urban Statistical Yearbook were incorporated. The estimated crude incidence rate of cervical cancer among permanent residents was 17.4/100,000 in mainland China, with an age-standardized incidence rate (ASIR) of 17.2/100,000. The largest disparities in cervical cancer crude incidence rate between permanent residents and household-registered populations were observed in Guizhou (2.4/100,000, 95% CI 1.9-2.9/100,000), Zhejiang (-1.2/100,000, 95% CI -1.8 to -0.6/100,000) and Tianjin (-1.1/100,000, 95% CI -1.5 to -0.7/100,000). The number of the estimated cervical cancer incident cases was 8948. Guangdong saw an increase of 887 cases, while Henan had a decrease of 1430 cases. Guizhou had the highest ASIR (28.1/100,000), and Beijing had the lowest ASIR (11.0/100,000). The significance of this study is that it improves the accuracy of cervical cancer data in China. These findings provide evidence for developing cervical cancer prevention and control strategies, and offer insights for other countries and regions facing migration challenges.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143031727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of JMT103 in patients with bone metastases from solid tumors: A randomized Phase Ib clinical trial.","authors":"Ran Ran, Hongtao Li, Tao Sun, Huan Zhou, Aimin Zang, Hongqian Guo, Hua Xie, Shikai Wu, Yong Yan, Xing Yin, Hailin Xiong, Hong Li, Jing Yuan, Juan Wang, Huiping Li, Jin Li","doi":"10.1002/ijc.35343","DOIUrl":"https://doi.org/10.1002/ijc.35343","url":null,"abstract":"<p><p>This study aimed to assess the efficacy and safety of three dosing regimens of JMT103 in patients with bone metastases from solid tumors. Eligible patients were randomly assigned to receive JMT103 subcutaneously, 120 mg every 4 weeks (Cohort 1), 120 mg every 8 weeks (Cohort 2), or 180 mg every 8 weeks (Cohort 3) for up to 49 weeks. The primary endpoint was change from baseline to Week 13 in creatinine-adjusted urinary N-telopeptide (uNTx/Cr). Two hundred and ninety-five patients were randomized, and 293 received at least one dose of JMT103, of whom 96 were assigned to Cohort 1, 97 were assigned to Cohort 2, and 100 were assigned to Cohort 3. The median (interquartile range) percentage reduction in uNTx/Cr at Week 13 was 80.0% (49.9%, 93.4%) in Cohort 1, 73.0% (34.5%, 94.0%) in Cohort 2, and 75.7% (40.4%, 92.0%) in Cohort 3, respectively. On-study skeletal-related events were reported by 3.1% of patients in Cohort 1, 6.2% in Cohort 2, and 7.0% in Cohort 3. Treatment-emergent adverse events occurred in 289 patients, 162 of whom were deemed treatment-related. The most common treatment-related adverse events were hypocalcemia (23.2%), hypophosphatemia (22.9%), and increased aspartate transaminase (11.9%). JMT103 demonstrated a good safety and a strong suppression of the bone turnover markers.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143031745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “Impact of era of diagnosis on cause-specific late mortality among 77 423 five-year European survivors of childhood and adolescent cancer: The PanCareSurFup consortium”","authors":"","doi":"10.1002/ijc.35284","DOIUrl":"10.1002/ijc.35284","url":null,"abstract":"&lt;p&gt;Byrne J, Schmidtmann I, Rashid H, et al. Impact of era of diagnosis on cause-specific late mortality among 77 423 five-year European survivors of childhood and adolescent cancer: The PanCareSurFup consortium. Int J Cancer 2022;150(3):406–419. doi:10.1002/ijc.33817.&lt;/p&gt;&lt;p&gt;In the article, the errors detailed below were identified. There were apparent errors in recoding the cause of death variable. The minor errors affected some of the text, tables, figures and Supplemental material. These changes do not affect either the conclusions nor the inferences to be drawn from this article.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Author byline and Affiliations&lt;/b&gt;&lt;/p&gt;&lt;p&gt;The affiliation number 25 has been deleted and the affiliations of the following authors have been corrected as listed below:&lt;/p&gt;&lt;p&gt;Cécile M. Ronckers&lt;sup&gt;18&lt;/sup&gt; | Milena Maule&lt;sup&gt;25&lt;/sup&gt; | Roderick Skinner&lt;sup&gt;26,27&lt;/sup&gt; | Eva Steliarova-Foucher&lt;sup&gt;28&lt;/sup&gt; | Monica Terenziani&lt;sup&gt;29&lt;/sup&gt; | Lorna Zadravec Zaletel&lt;sup&gt;30&lt;/sup&gt; | Lars Hjorth&lt;sup&gt;31&lt;/sup&gt; | Stanislaw Garwicz&lt;sup&gt;31&lt;/sup&gt;&lt;/p&gt;&lt;p&gt;The corrected list of affiliations is:&lt;/p&gt;&lt;p&gt;&lt;sup&gt;18&lt;/sup&gt;German Childhood Cancer Registry (GCCR), Division of Childhood Cancer Epidemiology, Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), Johannes Gutenberg University Mainz, Mainz, Germany&lt;/p&gt;&lt;p&gt;&lt;sup&gt;25&lt;/sup&gt;Childhood Cancer Registry of Piedmont, Department of Medical Science, University of Turin and Center for Cancer Prevention (CPO-Piemonte), Torino, Italy&lt;/p&gt;&lt;p&gt;&lt;sup&gt;26&lt;/sup&gt;Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Newcastle upon Tyne, UK&lt;/p&gt;&lt;p&gt;&lt;sup&gt;27&lt;/sup&gt;Department of Paediatric and Adolescent Haematology and Oncology, Great North Children's Hospital, Royal Victoria Infirmary, Newcastle Upon Tyne, UK&lt;/p&gt;&lt;p&gt;&lt;sup&gt;28&lt;/sup&gt;Section of Cancer Surveillance, International Agency for Research on Cancer, Lyon Cedex, France&lt;/p&gt;&lt;p&gt;&lt;sup&gt;29&lt;/sup&gt;Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy&lt;/p&gt;&lt;p&gt;&lt;sup&gt;30&lt;/sup&gt;Division of Radiotherapy, Institute of Oncology, Ljubljana, Slovenia&lt;/p&gt;&lt;p&gt;&lt;sup&gt;31&lt;/sup&gt;Department of Clinical Sciences Lund, Lund University, Skåne University Hospital, Pediatrics, Lund, Sweden&lt;/p&gt;&lt;p&gt;&lt;b&gt;Abstract&lt;/b&gt;&lt;/p&gt;&lt;p&gt;The sixth sentence of the Abstract paragraph originally read, “Compared to the diagnosis period 1960 to 1969, the mortality hazard ratio declined for first neoplasms (P for trend &lt;.0001) and for infections (P &lt; .0001); declines in relative mortality from second neoplasms and cardiovascular causes were less pronounced (P = .1105 and P = .0829, respectively).” This should read “Compared to the diagnosis period 1960 to 1969, the mortality hazard ratio declined for first neoplasms (P for trend &lt;.0001); declines in relative mortality from second neoplasms and cardiovascular causes were noted (&lt;i&gt;P&lt;/i&gt; = .0878 and &lt;i&gt;P&lt;/i&gt; = .0781, respectively).”&lt;/p&gt;&lt;p&gt;&lt;b&gt;Results&lt;/b&gt;&lt;/p&gt;&lt;p&gt;In the second paragraph, first sentence, it was originally stated “The f","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":"156 9","pages":"E8-E13"},"PeriodicalIF":5.7,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ijc.35284","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143031733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aggressive characteristics of tumor deposits in colorectal cancer highlight the need for staging refinement in patients with 0–3 metastatic lymph nodes","authors":"Xi'e Hu,&nbsp;Shuang Xie,&nbsp;Zhenyu Yang,&nbsp;Xin Zhao,&nbsp;Li Gong,&nbsp;Ping Yang,&nbsp;Lin Yang,&nbsp;Shoujia Wang,&nbsp;Guoqiang Bao,&nbsp;Xianli He","doi":"10.1002/ijc.35306","DOIUrl":"10.1002/ijc.35306","url":null,"abstract":"<p>Accurate staging is essential for the optimal management of patients with colorectal cancer (CRC). The role of tumor deposits (TDs) in CRC staging has been contentious due to a lack of comprehensive understanding of their clinical and biological traits. In this retrospective study, we analyzed large data from 5718 CRC patients diagnosed between 2011 and 2022, ensuring rigorous data collection and long-term follow-up. Patients with positive TDs displayed aggressive clinical features. The risk factors for TDs varied among patients with different backgrounds of lymph node (LN) involvement, and the numbers of TDs and metastatic LNs showed a significantly positive correlation. TDs significantly impacted CRC prognosis, resulting in unfavorable outcomes irrespective of LN status. To delve into the biological characteristics of TDs, we performed transcriptome sequencing, immunohistochemistry, and Kaplan–Meier analyses on tissue samples from the additional CRC cohort and The Cancer Genome Atlas datasets. TDs exhibited aggressive biological phenotypes that were distinct from primary tumors and metastatic LNs, characterized by elevated signatures of epithelial-mesenchymal transition, angiogenesis, and immune suppression. Cox proportional hazards analysis was then applied to reassess the appropriate role of TDs within the TNM staging system, revealing that the prognostic weightiness of TDs in CRC corresponded to N2a rather than N1 in patients with 0–3 LN metastases. Overall, our comprehensive analysis showed that TDs, with their aggressive clinical and biological characteristics, could optimize the staging of CRC, highlighting the need to refine their role within the TNM staging system.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":"156 9","pages":"1826-1839"},"PeriodicalIF":5.7,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142997074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increased serum NfL and GFAP levels indicate different subtypes of neurologic immune-related adverse events during treatment with immune checkpoint inhibitors","authors":"Christina Schmitt,&nbsp;Katharina J. Müller,&nbsp;Steffen Tiedt,&nbsp;Nora Kramer,&nbsp;Isabel Manger,&nbsp;Samuel Knauss,&nbsp;Leonie Müller-Jensen,&nbsp;Petra Huehnchen,&nbsp;Wolfgang Boehmerle,&nbsp;Florian Schöberl,&nbsp;Lucie Heinzerling,&nbsp;Louisa von Baumgarten","doi":"10.1002/ijc.35328","DOIUrl":"10.1002/ijc.35328","url":null,"abstract":"<p>Neurologic immune-related adverse events (nirAEs) represent rare, yet severe side effects associated with immune checkpoint inhibitor (ICI) therapy. Given the absence of established diagnostic biomarkers for nirAEs, we aimed to evaluate the diagnostic utility of serum Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP). Fifty-three patients were included at three comprehensive cancer centers, of these 20 patients with manifest nirAEs and 11 patients with irHypophysitis. Controls included patients without any irAE (<i>n</i> = 8) and other irAEs (<i>n</i> = 14). Using a single-molecule enzyme-linked immunosorbent assay (Simoa), serum levels were measured prior to, during and after the manifestation of (n)irAEs in 80 samples. Symptom severity of the (n)irAEs was graded according to the Common Criteria for Adverse Events (CTCAE) version 5.0. Serum NfL levels were significantly higher in the nirAE group (<i>n</i> = 20) compared to irHypophysitis (<i>n</i> = 11; <i>p</i> = .0025) and controls (<i>n</i> = 22; <i>p</i> = .0384). Subgroup analysis demonstrated a significant elevation of NfL in nirAEs of the peripheral nerves (PNirAE) in contrast to neuromuscular syndromes (NMirAE) (<i>p</i> = .0260). GFAP levels were highest in patients with nirAE affecting the central nervous system (CNSirAE) compared to PNirAE and NMirAE (<i>p</i> = .0064). Symptom severity of nirAEs was associated with increased levels of NfL and GFAP (<i>p</i> = .0069, .0092). Individuals with elevated NfL levels exhibited less favorable outcomes of the (n)irAEs (<i>p</i> = .0199). Measurement of NfL and GFAP may be helpful for the differentiation of the broad spectrum of nirAEs and may serve as an indicator of symptom severity. Further investigation is needed to evaluate their potential as diagnostic and prognostic biomarkers.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":"156 10","pages":"1961-1971"},"PeriodicalIF":5.7,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11924309/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142997051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Consensus statement for the diagnosis, treatment, and prognosis of kaposiform hemangioendothelioma","authors":"Jiangyuan Zhou,&nbsp;Tong Qiu,&nbsp;Zixin Zhang,&nbsp;Yuru Lan,&nbsp;Ran Huo,&nbsp;Bo Xiang,&nbsp;Siyuan Chen,&nbsp;Li Qiu,&nbsp;Chunchao Xia,&nbsp;Xuewen Xu,&nbsp;Jing Li,&nbsp;Yangyang Ma,&nbsp;Wei Yao,&nbsp;Zuopeng Wang,&nbsp;Changxian Dong,&nbsp;Zhongping Qin,&nbsp;Maozhong Tai,&nbsp;Lei Guo,&nbsp;Xin He,&nbsp;Song Gu,&nbsp;Li Li,&nbsp;Fang Hou,&nbsp;Yu Cai,&nbsp;Huaijie Wang,&nbsp;Jinhu Wang,&nbsp;Xian Jiang,&nbsp;Jiawei Zheng,&nbsp;Kai Li,&nbsp;Yi Ji","doi":"10.1002/ijc.35344","DOIUrl":"10.1002/ijc.35344","url":null,"abstract":"<p>Kaposiform hemangioendothelioma (KHE) is a rare vascular tumor that typically presents in infancy or early childhood. As awareness of KHE increases, it is imperative that the management of KHE be updated to reflect the latest evidence-based guidelines. The aim of this study was to integrate the literature and Chinese expert opinions to provide updated recommendations that will guide the diagnosis, treatment, and prognosis of patients with KHE. According to this consensus statement, 28 nationally peer-recognized experts in vascular anomalies and an expert in evidence-based medicine were assembled and formed three consensus subgroups. A series of key themes and questions were developed for each group, including recommendations for diagnosis, treatment, and prognosis. A systematic search was conducted for English-language articles published in PubMed and other relevant studies identified by the expert panel. A diagnosis of KHE necessitates the integration of clinical, imaging, and histologic features. The treatment of KHE should be tailored to the specific characteristics of each patient, including the size of the lesion, the presence of symptoms, the location, and the overall condition of the patient. In addition to focusing on the disease itself, it is also important to consider the complications of KHE and their impact on prognosis. The recommendations presented herein are intended to assist in the guidance of clinical practice and decision-making in patients with KHE, with the objective of improving patient outcomes.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":"156 10","pages":"1986-1994"},"PeriodicalIF":5.7,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142997081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to: Comments on “Associations of plasma omega-6 and omega-3 fatty acids with overall and 19 site-specific cancers: A population-based cohort study in UK Biobank”","authors":"Yuchen Zhang,&nbsp;J. Thomas Brenna,&nbsp;Ye Shen,&nbsp;Kaixiong Ye","doi":"10.1002/ijc.35334","DOIUrl":"10.1002/ijc.35334","url":null,"abstract":"","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":"156 10","pages":"2040-2046"},"PeriodicalIF":5.7,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142996737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing PD-L1 and PD-1 inhibitors plus bevacizumab combined with hepatic arterial interventional therapies in unresetable hepatocellular carcinoma: A single-center, real-world study","authors":"Minrui He,&nbsp;Wa Xie,&nbsp;Ze Yuan,&nbsp;Jinbin Chen,&nbsp;Juncheng Wang,&nbsp;Yizhen Fu,&nbsp;Zili Hu,&nbsp;Qi Meng,&nbsp;Wenqing Gao,&nbsp;Dandan Hu,&nbsp;Yaojun Zhang,&nbsp;Yangxun Pan,&nbsp;Zhongguo Zhou","doi":"10.1002/ijc.35341","DOIUrl":"10.1002/ijc.35341","url":null,"abstract":"<p>With the rise of anti-vascular endothelial growth factor antibody and programmed cell death-ligand 1 (PD-L1) regimens, particularly bevacizumab and atezolizumab, as first-line treatments for advanced hepatocellular carcinoma (HCC), there is a need to explore PD-L1 and programmed cell death 1 inhibitors in combination therapies for unresectable HCC (uHCC). Integrating systemic therapies with locoregional approaches is also emerging as a potent strategy. This study compares the outcomes of atezolizumab (PD-L1 inhibitor) and sintilimab (programmed cell death 1 inhibitor) with bevacizumab or its biosimilar, combined with hepatic arterial interventional therapies (HAIT) in uHCC patients. From January 2020 to September 2023, a retrospective analysis was conducted on 138 uHCC patients at Sun Yat-sen University Cancer Center. The cohort included 69 patients treated with atezolizumab with bevacizumab (Bev/Ate) and 69 with bevacizumab biosimilar with sintilimab (Bio/Sin), combined with HAIT. The propensity score matching was also employed to further explore the efficacy and safety. The median progression-free survival (mPFS) was 13.8 months for the Bev/Ate group and 10.0 months for the Bio/Sin group (<i>p</i> = 0.188). The Bev/Ate group showed significantly longer intrahepatic mPFS (HR 0.381; 95% confidence interval 0.176–0.824; <i>p</i> = .018) and higher overall response rates compared with the Bio/Sin group (60.87% vs. 31.88%, <i>p</i> = .001; 69.57% vs. 49.28%, <i>p</i> = .024) based on Response Evaluation Criteria in Solid Tumors v1.1 and modified Response Evaluation Criteria in Solid Tumors criteria. Treatment-related adverse events were similar between groups (<i>p</i> &gt; .050). Combining atezolizumab or sintilimab with bevacizumab or its biosimilar alongside HAIT provided similar overall PFS in uHCC patients. However, the atezolizumab-bevacizumab combination with HAIT showed superior intrahepatic PFS and control rates, warranting further validation.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":"156 10","pages":"1972-1985"},"PeriodicalIF":5.7,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142997078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}